Is there a circadian variation in 5-Fluorouracil (5FU) plasma concentration (Cp) given by continuous infusion?

被引：0
|
作者：
Strocchi, E
Camaggi, CM
Martoni, A
Sereni, A
Pannuti, R
Pittureri, C
Cacciari, N
Zamagni, C
Pannuti, F
机构：
[1] ANT Lab, Dept Organ Chem, Bologna, Italy
[2] S Orsola M Malpighi Hosp, Div Med Oncol, Bologna, Italy
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
243P
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [21] TOTAL-BODY CLEARANCE OF INFUSIONAL 5-FLUOROURACIL (5FU)
    FLOYD, R
    GRIFFITHS, J
    HORNBECK, C
    FRANKEL, S
    SHARP, T
    BYFIELD, J
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 395 - 395
  • [22] A phase I dose escalation of hydroxyurea (HU) in addition to continuous infusion 5-fluorouracil (5FU) in patients with advanced colorectal cancer
    Last, K
    Lofts, FJ
    Thompson, F
    Mansi, JL
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S14 - S14
  • [23] BLOOD URINE PARAMETERS FOR CONTINUOUS INFUSION CISPLATINUM (CP) BOLUS 5-FLUOROURACIL (5-FU) IN THE TREATMENT OF GASTROINTESTINAL MALIGNANCIES
    BELLIVEAU, JF
    CRABTREE, GW
    POSNER, MR
    WEITBERG, A
    WIEMANN, MC
    CUMMINGS, FJ
    GRIFFIN, H
    OLEARY, GP
    CALABRESI, P
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 168 - 168
  • [24] CONTINUOUS INFUSION (CI) OF 5-FLUOROURACIL (5FU) AND CISPLATIN (DDP) FOR METASTATIC COLORECTAL-CANCER (MCRC) AND OTHER GASTROINTESTINAL MALIGNANCIES
    MADAJEWICZ, S
    BURK, M
    DAINER, P
    FIORE, J
    JOHNSON, H
    OSTROW, S
    SCHUBACH, W
    VIOLA, M
    KENNEDY, D
    VITKUN, C
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 201 - 201
  • [25] The mismatch repair (MMR) complex hMutSα recognizes 5-fluorouracil (5FU) modified DNA:: a mechanism for 5FU sensitivity
    Tajima, A
    Cabrera, BL
    McMahon, H
    Doctolero, R
    Huang, S
    Carethers, J
    GASTROENTEROLOGY, 2003, 124 (04) : A21 - A21
  • [26] Adjuvant therapy with 5-fluorouracil (5FU) plus levamisole or 5FU plus radiotherapy in resected colorectal cancer.
    Aparicio, J
    Segura, A
    Santaballa, A
    Garcerá, S
    Yuste, A
    López, P
    Tormo, A
    Reynés, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S78 - S78
  • [27] RAPID ASSAY OF 5-FLUOROURACIL (5FU) IN PLASMA BY GC-CIMS AND STABLE ISOTOPE DILUTION
    MIN, BH
    GARLAND, WA
    RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1978, 22 (01): : 145 - 154
  • [28] ENZYMATIC CHANGES INDUCED BY THYMIDINE (TDR) AND 5-FLUOROURACIL (5FU) THERAPY
    SALSER, JS
    MARTIN, DS
    BALIS, ME
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 80 - 80
  • [29] PLASMA PHARMACOKINETICS OF 5-FU GIVEN BY CONTINUOUS INFUSION WITH ALLOPURINOL
    ERLICHMAN, C
    FINE, S
    ELHAKIM, T
    CANCER TREATMENT REPORTS, 1986, 70 (07): : 903 - 904
  • [30] Adsorption and Release of 5-Fluorouracil (5FU) from Mesoporous Silica Nanoparticles
    Azali, Nur Syazaliyana
    Kamarudin, Nur Hidayatul Nazirah
    Rahim, Ainul Rasyidah Abdul
    Nasir, Norzaidhatul Syifa'a Jamal
    Timmiati, Sharifah Najiha
    Jaafar, Nur Farhana
    MATERIALS TODAY-PROCEEDINGS, 2019, 19 : 1722 - 1729
12345